On the Alert for Cytokine Storm: Immunopathology in COVID-19: Arthritis and Rheumatology

L.A. Henderson, S.W. Canna, G.S. Schulert, S. Volpi, P.Y. Lee, K.F. Kernan, R. Caricchio, S. Mahmud, M.M. Hazen, O. Halyabar, K.J. Hoyt, J. Han, A.A. Grom, M. Gattorno, A. Ravelli, F. De Benedetti, E.M. Behrens, R.Q. Cron, P.A. Nigrovic

Research output: Contribution to journalArticlepeer-review


Poor outcomes in COVID-19 correlate with clinical and laboratory features of cytokine storm syndrome. Broad screening for cytokine storm and early, targeted antiinflammatory therapy may prevent immunopathology and could help conserve limited health care resources. While studies are ongoing, extrapolating from clinical experience in cytokine storm syndromes may benefit the multidisciplinary teams caring for patients with severe COVID-19. © 2020, American College of Rheumatology
Original languageEnglish
Pages (from-to)1059-1063
Number of pages5
JournalArthritis Rheum.
Issue number7
Publication statusPublished - 2020


  • cytokine
  • gamma interferon
  • interleukin 1
  • interleukin 18
  • interleukin 1beta
  • interleukin 6
  • antiinflammatory agent
  • biological marker
  • coronavirus disease 2019
  • cytokine storm
  • human
  • multidisciplinary team
  • Note
  • priority journal
  • Betacoronavirus
  • complication
  • Coronavirus infection
  • cytokine release syndrome
  • early intervention
  • immunology
  • pandemic
  • virology
  • virus pneumonia
  • Anti-Inflammatory Agents
  • Biomarkers
  • Coronavirus Infections
  • Cytokine Release Syndrome
  • Early Medical Intervention
  • Humans
  • Pandemics
  • Pneumonia, Viral


Dive into the research topics of 'On the Alert for Cytokine Storm: Immunopathology in COVID-19: Arthritis and Rheumatology'. Together they form a unique fingerprint.

Cite this